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ABSTRACT
Cardiac tissue engineering, which combines cells and biomaterials, is promising for limiting the se-
quelae of myocardial infarction (MI). We assessed myocardial function and scar evolution after
implanting an engineered bioactive impedance graft (EBIG) in a swineMI model. The EBIG comprises
a scaffold of decellularized human pericardium, green fluorescent protein-labeled porcine adipose
tissue-derived progenitor cells (pATPCs), and a customized-design electrical impedance spectroscopy
(EIS) monitoring system. Cardiac function was evaluated noninvasively by using magnetic resonance
imaging (MRI). Scar healing was evaluated by using the EIS system within the implanted graft. Addi-
tionally, infarct size, fibrosis, and inflammation were explored by histopathology. Upon sacrifice 1
month after the intervention,MRI detected a significant improvement in left ventricular ejection frac-
tion (7.5%64.9%vs. 1.4%63.7%;p= .038) and strokevolume (11.565.9ml vs. 364.5ml;p= .019) in
EBIG-treated animals. Noninvasive EIS data analysis showed differences in both impedance magni-
tude ratio (20.02 6 0.04 per day vs. 20.48 6 0.07 per day; p = .002) and phase angle slope
(20.18°6 0.24° per day vs.23.52°6 0.84° per day; p = .004) in EBIG comparedwith control animals.
Moreover, in EBIG-treated animals, the infarct size was 48% smaller (3.4%6 0.6% vs. 6.5%6 1%; p =
.015), less inflammation was found by means of CD25+ lymphocytes (0.656 0.12 vs. 1.266 0.2; p =
.006), and a lower collagen I/III ratio was detected (0.496 0.06 vs. 1.666 0.5; p = .019). An EBIG com-
posed of acellular pericardium refilled with pATPCs significantly reduced infarct size and improved
cardiac function in a preclinical model of MI. Noninvasive EIS monitoring was useful for tracking dif-
ferential scar healing in EBIG-treated animals, whichwas confirmed by less inflammation and altered
collagen deposit. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–9
SIGNIFICANCE
This article describes the development and testing of a new custom-designed engineered bioimpe-
dance graft (EBIG) to noninvasivelymonitormyocardial scar healing. The EBIGwasmade of a scaffold
of decellularizedhumanpericardium, green fluorescent protein-labeledporcine adipose tissue-derived
progenitor cells, and an electrical impedance spectroscopy (EIS) monitoring system. In a noninvasive
manner, cardiac function was evaluated by magnetic resonance imaging (MRI) and scar healing by a
customized-design EIS system incorporated within the implanted graft. A significant improvement in
MRI left ventricular ejection fraction was detected in EBIG-treated animals, and histopathology con-
firmed less inflammation and altered collagen deposit.
INTRODUCTION
Cardiac tissue engineering, which combines cells
andbiomaterials, is a promising therapyaftermyo-
cardial infarction(MI) [1].Themaingoalof thisnew
approach includes both the restoration of dam-
aged tissue and the recovery of cardiac function
to limit or prevent adverse ventricular remodeling
and end-stage heart failure. To this end, different
biomaterials are being tested (i.e., collagen, algi-
nate, hydrogel, and extracellular matrices) to pro-
vide a stable support for cell delivery in close
contact with the damaged tissue [2]. Microscopic
and ultrastructural scaffold topography is key for
cellular homing and migration to the target tissue
[3, 4]. Decellularized tissues offer a natural micro-
environment, driving cellular attachment, survival,
migration, proliferation, and differentiation [5, 6].
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Prat-Vidal et al. previously reported preliminary data on a
novel engineered bioactive impedance graft (EBIG) comprising
a scaffold of decellularizedhumanpericardium, green fluorescent
protein (GFP)-labeled porcine adipose tissue-derived progenitor
cells (pATPCs), and an electrical impedance spectroscopy (EIS)
monitoring system [7]. The functional impact of EBIG in a preclin-
ical model of MI and scar maturation characteristics remains
unknown. Accordingly, cardiac function was evaluated in a nonin-
vasive manner by using magnetic resonance imaging (MRI). Addi-
tionally, scar healingwasevaluatedbyusing a custom-designedEIS
system incorporated within the implanted graft in the acute MI
swine model.
MATERIALS AND METHODS
Experimental Design
After a left lateral thoracotomy, an MI was induced via double-
ligation of the first marginal branch of the circumflex artery,
1.5 cm distally from the atrioventricular groove (Prolene 5/0
W-8556 12-S, Ethicon, Somerville, NJ, http://www.ethicon.com)
[8]. After 30 minutes, the EBIG was attached over the infarcted
tissuewith 0.1–0.2ml of surgical glue (Glubran 2, CardioLink, Bar-
celona, Spain, http://www.cardiolink.es). Finally, the animals
were allowed to recover and housed for 1month before sacrifice.
In order to ensure that all animals had a similar MI, we analyzed
circulating troponin I (cTnI) and creatine kinase in serum samples
collected by jugular venipuncture at baseline and 2hours afterMI
induction. Cardiac biomarkers were measured in a fluorometric
immunoassay analyzer (AQT90 FLEX, Radiometer Medical ApS,
Brønshøj, Denmark, http://www.radiometer.com).
Twenty-six cross-bred Landrace3 large white swine (30.26
3.6 kg) were randomly distributed into three groups (Fig. 1): (a)
control arm (n = 10), MI induction treated with apposition of a
cell-free pericardial scaffold connected to the EIS system; (b)
EBIG-treated arm (n = 12), MI induction treated with the EBIG;
and (c) sham arm (n = 4), no MI, but the EBIG was implanted
on top of healthy myocardium.
All animal studies were approved by the local Animal Exper-
imentation Unit Ethical Committee (no. ES 100370001499) and
complied with all guidelines concerning the use of animals in re-
search and teaching as defined by the Guide for the Care and Use
of Laboratory Animals (NIH Publication No. 80-23, revised 1996).
Human pericardial sampleswere obtained afterwritten informed
consent from patients undergoing cardiac surgery. The local
ethics committee approved this study, and the protocol con-
formed to the principles outlined in the Declaration of Helsinki.
Engineered Bioactive Impedance Graft
Human pericardium obtained from patients undergoing cardiac
surgery was used as a biological scaffold (Fig. 2A). Pericardial
decellularization was performed as previously described [7].
Briefly, the tissue was immersed in 1% SDS for 72 hours and then
in 1% Triton-X for an additional 48 hours. Afterward, the mem-
branes were lyophilized with a vacuum pump to extract all fluids,
sterilizedwithg rays, and stored until use (Fig. 2B). Thirtyminutes
after MI induction, the metallic electrodes were separately an-
chored 1 cm apart in the thickness of the membrane (Fig. 2C,
2D). Then, the decellularized pericardium was rehydrated with
175 ml of Puramatrix hydrogel (BD Biosciences, San Jose, CA,
http://www.bdbiosciences.com), and in treated animals, the
EBIG included 2 3 106 GFP-pATPCs embedded in 175 ml of 10%
sucrose. Finally, to ensure jellification, 350ml ofa-minimal essen-
tial medium was applied (Fig. 2E). Then, the bioimpedance
devices, previously coatedwithbiocompatible polydimethylsilox-
ane silicone and sterilized (Fig. 2F), were located in a subcutane-
ous pocket in the left supraescapular zone (Fig. 2G). Eighteen
EIS systems were implanted (Fig. 2H) (seven animals in each
experimental group and four sham animals) and connected
to the EIS system (Fig. 2I, 2J) for active monitoring of MI scar
evolution. Finally, animals were individually housed with an
Figure 1. Study design. Abbreviations: EBIG, engineered bioactive impedance graft; EIS, electrical impedance spectroscopy; MI, myocardial
infarction; MRI, magnetic resonance imaging; n, number of pigs.
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ad-hoc-developed antenna for noninvasive online bioimpedance
signal transmission (Fig. 2K).
Noninvasive Cardiac Function Assessment
Cardiac MRI was performed at 1.5 T (Intera; Philips, Amsterdam,
TheNetherlands, http://www.usa.philips.com) in all animals byus-
ing a four-channel phased array surface coil (SENSE Body Coil, Phi-
lips). Breath-held, ECG-gated cine steady-stateprecessionMRIwas
acquired (TR/TE4.1/2.1ms; flip angle60°; fieldof view[FOV]3203
320mm;matrix 1603 160 pixels; slice thickness 7mm;bandwidth
1,249.7Hz per pixel). Delayed enhancement imageswere acquired
after intravenousgadolinium(0.2ml/kg)usingaphase-sensitive in-
version recovery sequence (TR/TE 4.9/1.6ms; flip angle 15°; inver-
sion time 157 ms; FOV 330 3 330 mm; matrix 224 3 200 pixels;
slice thickness 10mm; bandwidth 282.3 Hz per pixel). Left ventric-
ular ejection fraction (LVEF), cardiac output (CO), stroke volume
(SV), left ventricular end-systolic volume (LVESV), left ventricular
end-diastolic volume (LVEDV), and left ventricular end-diastolic
wall mass (LVEDWM) were measured at baseline, 48 hours after
MI, andbefore sacrifice. Independent blinded investigators carried
out MRI data acquisition and analysis.
Noninvasive Scar Maturation Assessment
Impedance (magnitude and phase angle) was acquired every 5
minutes at 14 frequencies logarithmically spaced between 100
and 200 kHz. System temperature and battery voltage were also
acquired. The contents of the EIS systemswere downloaded after
explantation through the Zigbee radio link controlled by a custom
Figure 2. Engineered bioactive impedance graft (EBIG). Photographs show the different steps of EBIG creation and implantation. (A, B):Native
human (A) and decellularized and lyophilized pericardium (B). Scale bars = 1 cm. (C, D): Metallic electrodes placement 1 cm spaced. (E): Re-
hydrationof the scaffoldwith orwithout cells. (F,G):Bioimpedancedevice coatedwith silicone (F) and its implantation in a subcutaneous pocket
in the left supraescapular zone (G). (H, I): Adhesion of the engineered construct to the myocardial infarction (H) and the connection with the
electrical impedance spectroscopy system (I). (J): Image showing the EBIG implanted in a swine. (K): Animal housing under an antenna non-
invasively receiving and transmitting the bioimpedance signal.
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application (LabView, National Instruments, Austin, TX, http://
www.ni.com). The impedance measurements were processed
with amedian filter (n = 25, equivalent to 2 hours) to exclude sud-
den artifacts. Subsequently, a moving average filter (n = 150,
equivalent to 12.5 hours) was used to smooth the time series
by using the zero-shift double pass filter filtfilt (Matlab, Math-
Works,Natick,MA,http://www.mathworks.com). Inorder to cor-
rect for long artifacts, the magnitude at the highest frequency
(200 kHz) was subtracted from the magnitude at the other fre-
quencies. Two estimators were chosen to display the integrity
of the tissue in the monitored area: the slope of the time course
of the impedance magnitude ratio between low frequency (LF;
1 kHz) and high frequency (HF; 100 kHz), and the slope of the time
course of the phase angle difference between the LF and HF. The
rationale for these estimators is presented in Discussion.
Histopathology Examination
Sacrifices were performed an average of 30.66 3 days after MI
with an overdose of anesthesia. After lateral thoracotomy, the
hearts were excised. Left ventricle (LV) infarct size was measured
by examination of sections obtained 1.5 cm distally to the artery
ligation by using the following equation: infarct size (%) = [(LV
infarct area)/(LV total area)] 3 100. Quantitative morphometric
and histological measurements were completed with Image-Pro
Plus software (version 6.2.1; Media Cybernetics, Rockville, MD,
http://www.mediacy.com).
On 4-mmparaffin slices, modified Gallego’s andMasson’s tri-
chrome and Picrosirius Red staining were performed to analyze
both pathological and histological changes and collagen deposi-
tion (type I red/yellow and type III green) under a computer-
associated Leica DMI 6000B (Leica, Wetzlar, Germany, http://
www2.leicabiosystems.com) microscope with a polarized filter.
Frozen sections of 10 mm were stained by using biotinylated
GSLI B4 isolectin (1:25; Griffonia simplicifolia lectin I B4, Vector
Laboratories, Burlingame, CA, http://vectorlabs.com), smooth
muscle actin (SMA; 1:50; Sigma-Aldrich Quı´mica SL, Madrid,
Spain, http://www.sigmaaldrich.com), and elastin (1:100;
Abcam, Cambridge, MA, http://www.abcam.com) antibodies
to quantify vessel area and detect blood vessels within the scaf-
fold. For the inflammatory state study, CD3 (1:100) and CD25 (1:
10) (Bio-Rad, Hercules, CA, http://www.bio-rad.com) antibodies
were applied to determine the presence of lymphocytes and
activated lymphocytes, respectively, in the infarct zone. Finally,
to study the endothelial and cardiac differentiation of GFP-
pATPCs, and proliferation of cardiomyocytes, anti-GFP (1:1000:
Figure 3. Noninvasive cardiac function and morphometric analysis. (A): T1 short-axis delayed enhancement images from control and EBIG-
treated animal afterMI and after 30 days of follow-up. (B, C): LVEF and SV at baseline and 30 days after MI in control and EBIG-treated animals.
Data for individual pigs (dots) and theD (6SEM) are shown.p,p= .038; †,p= .019. Dotted red lines indicate themean evolution over time. (D, E):
Representative heart sections from control and EBIG-treated pigs showing the infarcted area of the LV. (F): Percentage of the LV infarct area
measured in EBIG-treated pig hearts compared with the control group after 30 days of follow-up. ‡, p = .015. Data represent mean 6 SEM.
Abbreviations: EBIG, engineered bioactive impedance graft; LV, left ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
SV, stroke volume.
4 Noninvasive Assessment of Myocardial Healing
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
ID: srinivasanv Time: 19:22 I Path: Z:/SCTM/Vol00602/170005/Comp/APPFile/JW-SCTM170005
650 oninvasive ssess ent of yocardial ealing
Oc 2016 The Authors STE ELLS RA SLATI L E I I
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Abcam), c-Kit (1:50; Bioss, Woburn, MA, http://biossusa.com),
MEF-2 (1:50; MyBiosource, San Diego, CA, http://www.
mybiosource.com), cardiac troponin I (1:200; Santa Cruz Bio-
technology, Dallas, TX, http://www.scbt.com), NKX2.5 (1:50;
Bioss), cardiac troponin T (1:50; Bio-Rad), SMA (1:50; Sigma-
Aldrich), von Willebrand factor (vWF) (1:100; BD Biosciences,
Franklin Lakes, NJ, http://www.bdbiosciences.com), CD31 (1:50;
Abcam), and Ki67 (1:100; Santa Cruz Biotechnology) antibodies
were used. Alexa Fluor 488-conjugated streptavidin, Alexa Fluor
488 and 568 (1:500; Thermo Fisher Scientific Life Sciences, Oak-
wood Village, OH, https://www.thermofisher.com), and Cy2,
Cy3, andCy5 (1:500; Jackson ImmunoResearchLaboratories,West
Grove, PA, https://www.jacksonimmuno.com) secondary anti-
bodies were also used. All sections were counterstained with
49,6-diamidino-2-phenylindole (1:10,000; Sigma-Aldrich) and ana-
lyzedbyconfocalmicroscopy(AxioObserverZ1,Zeiss,Oberkochen,
Germany, http://www.zeiss.com).
Statistical Analysis
Data are representedas themean6 SEM. Statistical analyseswere
performedbyusing theStudent t test, one-wayanalysis of variance
(ANOVA) with the Tukey’s procedure for multiple comparisons,
and the Mann-Whitney test for nonparametric data, using SPSS
19.0.1 (IBM, Armonk, NY, http://www.ibm.com).MRI datawere
analyzed as repeated measures by using ANOVA with the
Greenhouse-Geisser correction. Bioimpedance data analyses were
performedwith the paired samples t test using SigmaStat software
(Systat Software, Inc., San Jose, CA, https://systatsoftware.com).
Values of p, .05 were considered significant.
RESULTS
Two animals died during MI induction due to ventricular fibrilla-
tion, and threewere excluded from the study after postoperative
infections. Therefore, 21animalswere included in theexperimen-
tal protocol in the control (n = 8), EBIG-treated (n = 10), and sham
(n = 3) groups (Fig. 1). Swine were sacrificed at predefined times
(p= .5betweengroups). In all animals, thegraftwas seencovering
the infarct area; absence of deleterious graft-driven effects was
detected in sham animals (supplemental online Fig. 1). Baseline
infarct size between EBIG-treated and control animals was not
significantly different as assessed by the necrosis biomarkers cTnI
and creatine kinase-MB (0.396 0.1 vs. 0.326 0.1 mg/l, p = .63;
and 0.59 6 0.09 vs. 0.546 0.14 mg/l, p = .75, respectively).
Cardiac Function Assessment
Baseline cardiac function did not differ between the EBIG-treated
and control groups in LVEF (55.8%6 2.2% vs. 56.5%6 2.8%; p =
.85), CO (2.16 0.1 vs. 2.26 0.1 l/min; p = .44), SV (24.16 1.6 vs.
25.1 6 1.3 ml; p = .64), LVESV (19.7 6 2.1 vs. 19.6 6 1.6 ml;
Figure 4. Green fluorescent protein-adipose tissue-derived progenitor cell (GFP-ATPC) endothelial and cardiac differentiation. (A): Immuno-
histochemistry images from border, infarct, and EBIG zones of treated animals showing positive GFP-ATPCs (green) and IsoB4, SMA, vWF, and
CD31 (red) endothelial antibodies. (B): Representative images from border, infarct, and EBIG zones of treated animals showing positive GFP-
ATPCs (green) andNKX2.5, cKit, and circulating troponin I (white), andMEF2 (red) and cardiac troponin T (white), and cardiacmarkers. Nuclei are
counterstained with 49,6-diamidino-2-phenylindole (blue). Scale bars = 50 mm. Abbreviations: EBIG, engineered bioactive impedance graft;
IsoB4, GSLI B4 Isolectin; SMA, smooth muscle actin; vWF, von Willebrand factor.
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p= .96), LVEDV (43.863.2 vs.44.761.8ml;p = .88), and LVEDWM
(42.96 2.2 vs. 44.16 1.6 g; p = .68) (supplemental online Table 1).
The ANOVA test with Greenhouse-Geisser post hoc correc-
tion showed differences over time in LVEF (7.5% 6 4.9% vs.
1.4% 6 3.7%; p = .038) and SV (11.5 6 5.9 ml vs. 3 6 4.5 ml;
p = .019) between EBIG-treated and control animals, respectively
(Fig. 3A–3C). In contrast, nodifferenceswere found inCO (p= .13),
LVESV (p = .91), LVEDV (p = .07), or LVEDWM (p = .56).
To understand the MRI functional benefit in the EBIG-
treated arm, the infarct size and cellular differentiation were
assessed. After digital morphometric analysis, LV infarct size
was 48% smaller in EBIG-treated than control animals (3.4% 6
0.6% vs. 6.5%6 1%, respectively; p = .015) (Fig. 3D–3F). Proper
adhesion of the implanted graftwith subjacentmyocardiumwas
observed in all control and EBIG-treated animals (supplemental
online Fig. 2A–2D).
Cell Proliferation and GFP+-pATPC Endothelial and
Cardiac Differentiation
As supplemental online Figure 3 depicts, there were cardiomyo-
cytes expressing the cell proliferative marker Ki67 in the border
zone of treated animals. However, Ki67-positive cells were not de-
tected in the infarct core. Additionally, upon sacrifice, grafts from
EBIG-treated and control animals showed vessel formation, some
ofwhichwere positive for SMA,which is indicative of the existence
of a vascular media layer (supplemental online Fig. 2E, 2F). More-
over, GFP+-pATPCs de novo expressed the endothelial markers
IsoB4, SMA, vWF, and CD31+ within the EBIG and at the infarct
zone, suggesting graft-driven neovascularization (Fig. 4A). Relative
tocardiacdifferentiationanalysis,we foundthatbothGFP+-pATPCs
within the graft and those that migrated to the infarct area were
positive for NKX2.5, cKit, MEF2, cTnI, and cTnT. (Fig. 4B).
Scar Evolution Monitoring
Out of the 18 systems implanted (7 per experimental group and 4
in the sham group), 11 provided useful data (4 controls, 4 EBIG-
treated, and 3 sham). Four of the remaining EIS systems were
in deceased or excluded animals, and the remaining three stop-
ped measuring after 1–3 days for unknown reasons.
Within 8days, significant differenceswereobserved between
EBIG-treated and control animals. Figure 5 shows the time course
of the impedance magnitude ratio (Fig. 5A) and phase angle dif-
ference (Fig. 5B) in the three groups. The magnitude ratio slope
estimator was 20.48 6 0.07 per day for controls and 20.02 6
0.04 per day for EBIG-treated (p = .002). There was also a signif-
icant difference between the control and sham groups (20.156
0.07 per day; p = .013), whereas no differences were found be-
tween the EBIG-treated and sham groups (p = .39).
Regarding the phase angle difference slope estimator, the re-
sults were 23.52° 6 0.84° per day for controls and 20.18° 6
0.24° per day for EBIG-treated (p = .004). There was also a signif-
icant difference between the control and shamgroups (21.08°6
0.17° per day; p = .03). The slopes were calculated as the first-
order coefficient of the linear regression for every magnitude ra-
tio and phase difference time courses without any normalization.
Figure 5 shows box plots of the magnitude ratio slope estimator
(Fig. 5A) and the phase angle difference slope estimator (Fig. 5B).
To correlate the EIS findings with tissue differences between
groups, collagen content and inflammationwere examined by us-
inghistopathological techniques. Collagen contentwasmeasured
Figure 5. Electrical impedance spectroscopy-derived tissue-state evolution estimators. Time course of the impedancemagnitude ratio (A) and
phase angle difference (B) in the control, EBIG-treated, and sham groups is shown. The curves show1 of every 100measurement points for sake
of clarity and represent the average curve for each group (control, circles, average of n = 4; EBIG-treated, triangles, average of n = 4; sham,
squares, average of n = 3). The three curves have been normalized to have the same origin to make the comparison easier. The dotted regions
around the regression lines represent the 95%confidence interval for the regression. Both themagnitude ratio andphase angle difference show
a clearly decreasing slope for the control group, whereas they remain almost constant for the EBIG-treated and sham groups. These results are
consistent with the transition to scar tissue for the control group and the existence of normal-like tissue in the EBIG-treated and sham groups.
(A): At the bottom is the box plot of the magnitude ratio slope estimator. p, p = .002; †, p = .013. (B): At the bottom appears the box plot of the
phase angle difference slope estimator, which also displayed a significant difference between controls and the other two groups. ‡, p = .004; x,
p = .03. The means and confidence intervals can be found in Results. Abbreviations: EBIG, engineered bioactive impedance graft; HF, high fre-
quency; LF, low frequency.
6 Noninvasive Assessment of Myocardial Healing
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
ID: srinivasanv Time: 19:22 I Path: Z:/SCTM/Vol00602/170005/Comp/APPFile/JW-SCTM170005
652 oninvasive ssess ent of yocardial ealing
Oc 2016 The Authors STE ELLS RA SLATI L E I I
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
after Picrosirius red staining. Upon sacrifice, collagen I (9.6% 6
1.4% vs. 17.2% 6 3.9%; p = .1), collagen III (19.5% 6 1.0% vs.
15.8% 6 3.3%; p = .31), collagen volume fraction (29.1% 6
1.9% vs. 32.9% 6 4.6%; p = .46), and the collagen I/III ratio
(0.5 6 0.1 vs. 1.7 6 0.5; p = .019) were analyzed in the infarct
cores of EBIG-treated comparedwith control animals, respectively
(Fig. 6A–6E). The inverse collagen I/III ratio in EBIG-treated animals
was also confirmedwhen relative content of collagen I and III were
comparatively assessed in control (17.2% 6 3.9% vs. 15.8% 6
3.3%, respectively; p = .79) and EBIG-treated (9.6% 6 1.4% vs.
19.5%6 1.0%, respectively; p, .001) animals (Fig. 6F).
Vascular Density and Inflammation Analyses
After Isolectin B4 staining, no differences in the vascularized area
between treated and controlMI groups in remote (1.66%6 0.24%
vs. 1.3%86 0.21%, respectively; p = .41), infarct (0.9%6 0.27% vs.
0.87%6 0.48%, respectively; p = .96), and border (1.08%6 0.16%
vs. 0.79%6 0.18%, respectively; p = .32) zones were found (data
not shown). After 30 days, in all implanted bioprostheses some
SMA-positive vessels were detected (supplemental online Fig.
2E, 2F). Analysis of inflammation at the infarct core showed no dif-
ferences in CD3+ content (p = .49) between groups; however,
CD25+content (0.65 6 0.12 vs. 1.26 6 0.20; p = .001) and the
CD25+/CD3+ ratio (0.23 6 0.04 vs. 0.61 6 0.06; p , .001) were
lower in EBIG-treated animals (Fig. 6G–6K).
DISCUSSION
In the present study, we focused on a noninvasive assessment of
cardiac function and scar healing using cardiacMRI and EIS to ob-
serve changes induced by a novel EBIG applied in a preclinical
model ofMI in swine. Twomain conclusions emerge from our re-
sults: First, the increase in cardiac contractility (assessed by LVEF)
in the EBIG-treated groupwasmore than fivefold higher than that
of controls; second, the EBIG positively impacted the healing pro-
cess, providing impedance values similar to those of sham-
operated animals, and altered scar collagen content.
Indeed, the remarkable cardiac function benefits with the
EBIG in terms of LVEF and SV improvement by MRI analysis are
in agreement with the 48% reduction in infarct size in EBIG-
treatedanimals. Similar, but lower-magnitude, benefitswerepre-
viously described when adipose-derived progenitor cells were
implanted using different routes of administration (intramyocar-
dial injection [9–11], intracoronary infusion [11], or peripheral
intravenous delivery [12]) in murine and swine MI models.
Adipose-derived progenitor cells tested in cardiac regeneration
Figure 6. Myocardial fibrosis and inflammation. (A, B): Sirius red-stained images exhibiting collagen (red) and healthy muscle (yellow) in the
infarct core from control and EBIG-treated animals. (C, D): Polarized lightmicroscopy images show fibrils of collagen I (red/yellow) and collagen
III (green) in the same sections. Scale bars = 50 mm. (E): Collagen I/III ratio measured on polarized light images. p, p = .019. (F): Percentage of
collagen I and IIImeasured onpolarized light images. †, p, .001. (G–J):Representative images of CD3 (green) andCD25 (red) at3400 (G,H) and
3630 (I, J) in the infarct core from control and EBIG-treated groups. Scale bars = 50 mm (G, H) and 20 mm (I, J). (K): Percentage of CD3- and
CD25-positive cells and CD25/CD3 ratio. ‡, p = .001; x, p, .001. Data represent themean6 SEMmeasurement. Abbreviations: ColI, collagen I;
Col III, collagen III; CVF, collagen volume fraction; EBIG, engineered bioactive impedance graft.
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therapies may be of subcutaneous [10–12] or cardiac origin [9,
13]. Bayes-Genis et al. previously demonstrated that cardiac
adipose-derived progenitors were more committed toward a
cardiac-like phenotype than those of subcutaneous origin [9].
Moreover, when seeded into the scaffold, these cells showed
repopulation and viability levels suitable for in vivo implantation
[7]. In this study, upon sacrifice, we were able to find GFP+ cells
within both the EBIG and in underlying myocardium de novo
expressing cTnI and NKX2.5. cTnI plays a key role inmature sarco-
mere organization, andNKX2.5 is central in activating the cascade
of cardiomyogenic genes. Thus, it is likely that pATPCs are partly
responsible for the beneficial effects of the EBIG because many
studies have reported that ATPCs secrete factors such as adipo-
kines, growth factors, and proteins from the extracellular matrix
that exert an important role in cardiac regeneration [14]. Evidence
is also accumulating showing that adipose-derived hormones can
offer cardioprotective effects, including attenuation of cardiomyo-
cyte apoptosis and reduction of infarct size [8]. Finally, neovascula-
rization of the graft and underlying myocardium has also been
suggested as a putative mechanism to limit infarct size [6]. In line
withthis,despitenovesseldensitydifferences in infarct core,within
the graft, the scar, and the remote myocardium we found vessels
positive for GFP, IsoB4, SMA, vWF, and CD31, but not in remote
myocardium. In point of fact, GFP+ pAPTCs within the scaffold also
expressed SMA. Regarding cardiomyocyte proliferation, and in
agreement with previous studies [15], the limited number of newly
formedcardiomyocytes identified inEBIG-treatedanimalsmayonly
have a low contribution to the significant improvement observed.
Interestingly, to noninvasively monitor online myocardial scar
evolution over 30 days, the grafts of sham, control, and EBIG-
treated animals were connected to a customized EIS. Previous
measurements of in vitro and in vivomyocardium in both normal
and healed infarction states have been reported, displaying a
frequency-dependent higher impedance for normal tissue and a re-
sistivebehavior for scar tissue [16, 17].Consequently, a gradual evo-
lution betweenboth states,with time-decreasing impedance at low
frequencies, couldbeexpected in the transition tohealed scar tissue
in control animals,whereas impedancesatall frequencies should re-
main constant in EBIG-treated animals. Our initial aim was to fit all
measurements to the Cole model for impedance and to study the
time course of the model parameters to obtain information about
the structural changesundergoneby the tissue. Thedifficulty inper-
forming suitable calibration because of differences in electrode im-
pedances and in capacitive coupling between the cables and the
animal’s body forced us to abandon this goal and to define estima-
tors basedon low- andhigh-frequencymeasurements. The variabil-
ity between subjects, as well as possible differences in the cell
constant defined by interelectrode distance, made it necessary to
define relative estimators like themagnitude ratio and phase angle
difference between low- and high-frequency measurements. Fi-
nally, the slope of the time course of both the magnitude ratio
and phase difference showed significant differences between the
control and the EBIG-treated/sham animals. According to EIS re-
sults, the main healing changes occurred before the 8th day after
the infarct, as shown by ample histopathology evidence [18]. Both
themagnitude ratioandphaseangledifferenceshowedaclearlyde-
creasing slope for the control group, whereas it remained almost
constant for the EBIG-treated and sham groups. These results are
consistent with the transition to scar tissue in the control group
and the preservation of myocardial tissue (at least from an imped-
anceperspective) inEBIG-treatedanimals. Inaccordance,analysisof
myocardial fibrosis on the infarct core showed a lower collagen I/III
ratio in EBIG-treated animals due to less collagen I deposition and
higher collagen III, which is eventually replaced by healthy tissue.
Because inflammation isalsoakeystep inmyocardialhealingafter
MI injury, we explored the impact of EBIG as an inflammatory modu-
lator. Indeed, fewer activated lymphocytes accumulated in EBIG-
treated animals, a phenomenon most likely caused by the adipose
progenitors contained within the graft. Perea-Gil et al. have reported
the immunomodulatory potential of cardiac adipose tissue progeni-
tors abrogating T-cell alloproliferation in vitro [19]. A key event in
graft rejection is the activation and proliferation of the recipient’s
lymphocytes, particularly T cells. Inhibition of T-cell activation (CD25+)
is observed in patients under immunosuppressive treatment [20].
CONCLUSION
An advanced EBIG composed of acellular human pericardium
refilled with pATPCs significantly reduced infarct size and im-
proved cardiac function in a preclinical model of MI. In this con-
text, the integrationof a sophisticatednoninvasive EISmonitoring
systemwas useful to analyze the evolution of myocardial healing
in EBIG-treated animals. Collectively, from an EIS perspective,
myocardial tissue was preserved in EBIG-treated animals despite
MI induction, which was confirmed by histopathological mea-
surements of less inflammation and altered collagen I/III ratio.
ACKNOWLEDGMENTS
Wethank L.Herna´ndez, B. Ferna´ndez, and J.Maestre for technical as-
sistance in the animal surgeries and MRI analysis. We also thank the
reviewers and editor for invaluable advice. This work was supported
by Ministerio de Economı´a y Competitividad Grants SAF2011-30067
andSAF2014-59892;Fundacio´ LaMARATO´deTV3Grants201516and
201502; Fundacio´ Daniel Bravo Andreu; Sociedad Espa~nola de Cardi-
ologı´a; Societat Catalana de Cardiologia; Generalitat de Catalunya
Grant SGR 2014; and Acade`mia de Cie`ncies Me`diques i de la Salut
de Catalunya i de Balears. This work has also been funded by Red
deTerapiaCelularProjectRD12/0019/0029,Redde Investigacio´nCar-
diovascular Project RD12/0042/0047, and Fondo de Investigacio´n
Sanitaria, Instituto de Salud Carlos III Project FIS PI14/01682 as part
of the Plan Nacional de I+D+I and cofounded by ISCIII-Sudireccio´n
General de Evaluacio´n y el Fondo Europeo de Desarrollo Regional.
AUTHOR CONTRIBUTIONS
C.G.-M.: conception and design, animal experimentation, collection
and/or assembly of data, data analysis and interpretation, manu-
script writing; R.B.: collection and/or assembly of data, data analysis
and interpretation, bioimpedance device creation, final approval of
manuscript; C.S.-B. and I.D.-G.: collection and/or assembly of data,
data analysis and interpretation, animal experimentation; C.P.-V.,
V.C., and A.L.-V.: collection and/or assembly of data, data analysis
and interpretation; F.M.S.-M.: provision of study material, final ap-
proval of manuscript; P.B.-F.: collection and/or assembly of data,
data analysis and interpretation, bioimpedance device creation;
I.P.-G.: collection and/or assembly of data; S.R.: manuscript writing,
final approval ofmanuscript; A.B.-G.: conception and design, manu-
script writing, final approval of manuscript.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
The authors indicated no potential conflicts of interest.
8 Noninvasive Assessment of Myocardial Healing
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
ID: srinivasanv Time: 19:22 I Path: Z:/SCTM/Vol00602/170005/Comp/APPFile/JW-SCTM170005
654 oninvasive ssess ent of yocardial ealing
Oc 2016 The Authors STE ELLS RA SLATI L E I I
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
REFERENCES
1 Vunjak-Novakovic G, Tandon N, Godier A
et al. Challenges in cardiac tissue engineering.
Tissue Eng Part B Rev 2010;16:169–187.
2 Ga´lvez-Monto´nC, Prat-VidalC,RouraSetal.
Update: Innovation in cardiology (IV). Cardiac tis-
sue engineering and the bioartificial heart. Rev
Esp Cardiol (Engl Ed) 2013;66:391–399.
3 Moroni F, Mirabella T. Decellularized ma-
trices for cardiovascular tissue engineering. Am
J Stem Cells 2014;3:1–20.
4 BadylakSF,FreytesDO,GilbertTW.Extracel-
lularmatrix asabiological scaffoldmaterial: Struc-
ture and function. Acta Biomater 2009;5:1–13.
5 Midwood KS, Williams LV, Schwarzbauer JE.
Tissue repair and the dynamics of the extracellular
matrix. Int J BiochemCell Biol 2004;36:1031–1037.
6 Ga´lvez-Monto´n C, Fernandez-Figueras
MT, Martı´ M et al. Neoinnervation and neovas-
cularization of acellular pericardial-derived
scaffolds in myocardial infarcts. Stem Cell Res
Ther 2015;6:108.
7 Prat-Vidal C, Ga´lvez-Monto´n C, Puig-
Sanvicens V et al. Online monitoring of myo-
cardial bioprosthesis for cardiac repair. Int J
Cardiol 2014;174:654–661.
8 Ga´lvez-Monto´n C, Prat-Vidal C, Roura S
et al. Transposition of a pericardial-derived
vascular adipose flap for myocardial salvage af-
ter infarct. Cardiovasc Res 2011;91:659–667.
9 Bayes-Genis A, Soler-Botija C, Farre´ J et al.
Human progenitor cells derived from cardiac
adipose tissue amelioratemyocardial infarction
in rodents. J Mol Cell Cardiol 2010;49:771–780.
10 Soler-BotijaC,Bago´ JR, Llucia`-Valldeperas
A et al. Engineered 3D bioimplants using elasto-
meric scaffold, self-assembling peptide hydro-
gel, and adipose tissue-derived progenitor
cells for cardiac regeneration. Am J Transl Res
2014;6:291–301.
11 GautamM,FujitaD, KimuraKet al. Trans-
plantation of adipose tissue-derived stem cells
improves cardiac contractile function and elec-
trical stability in a rat myocardial infarction
model. J Mol Cell Cardiol 2015;81:139–149.
12 RigolM, SolanesN, Farre´ J et al. Effects of
adipose tissue-derived stem cell therapy after
myocardial infarction: Impactof the routeof ad-
ministration. J Card Fail 2010;16:357–366.
13 Jun Hong S, Rogers PI, Kihlken J et al. In-
travenous xenogeneic transplantation of hu-
man adipose-derived stem cells improves left
ventricular functionandmicrovascular integrity
in swine myocardial infarction model. Catheter
Cardiovasc Interv 2015;86:E38–E48.
14 Kokai LE,MarraK, Rubin JP.Adipose stem
cells: Biology and clinical applications for tissue
repair and regeneration. Transl Res 2014;163:
399–408.
15 Anversa P, Leri A. Innate regeneration in
the aging heart: Healing fromwithin. Mayo Clin
Proc 2013;88:871–883.
16 Schwartzman D, Chang I, Michele JJ et al.
Electrical impedance properties of normal and
chronically infarcted left ventricular myocar-
dium. J Interv Card Electrophysiol 1999;3:
213–224.
17 WarrenM, Brago´s R, CasasO et al. Percu-
taneous electrocatheter technique for on-line
detection of healed transmural myocardial in-
farction. Pacing Clin Electrophysiol 2000;23:
1283–1287.
18 Mitchell RS, Kumar V, Abbas AK et al.
Robbins Basic Pathology. 8th ed. Philadelphia,
PA: Saunders, 2009.
19 Perea-Gil I, Monguio´-Tortajada M,
Ga´lvez-Monto´n C et al. Preclinical evaluation
of the immunomodulatory properties of car-
diac adipose tissue progenitor cells using um-
bilical cord blood mesenchymal stem cells: A
direct comparative study. Biomed Res Int
2015;2015:439808.
20 ShipkovaM,Wieland E. Surfacemarkers
of lymphocyte activation and markers of cell
proliferation. Clin Chim Acta 2012;413:
1338–1349.
See www.StemCellsTM.com for supporting information available online.
Ga´lvez-Monto´n, Brago´s, Soler-Botija et al. 9
www.StemCellsTM.com ©AlphaMed Press 2016
ID: srinivasanv Time: 19:22 I Path: Z:/SCTM/Vol00602/170005/Comp/APPFile/JW-SCTM170005
l - t , r  , l r- tij t l. 655
. ll . Oc 2016 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
